VALIDATION AND EVALUATION OF AN HPLC METHOD FOR QUANTIFICATION OF VITAMIN D3 IN PHARMACEUTICAL FORMULATIONS.

In accordance with the guidelines provided by ICH Q2 (R1), the analytical procedure that you have described for quantifying vitamin D-3 through the use of HPLC is quite comprehensive and has been thoroughly validated. The apparatus appears to be reliable, as it consists of a C-18 column, a mobile phase consisting of methanol and water, and detection at 264 nm, which is an adequate wavelength for vitamin D-3 identification. The flow rate of 1.2 millilitres per minute appears to be well optimised, and it is encouraging to observe that the method is linear (r2 = 0.999) between 0.25 and 1.25 microgrammes per millilitre across the concentration range. The accuracy of the procedure, which is proved by the recovery percentage that falls between 95 and 105%, in conjunction with a relative standard deviation (RSD) that is less than 2%, suggests that the method is both exact and trustworthy. The low limit of detection (LOD) of 0.0001 µg/mL and the low limit of quantification (LOQ) of 0.0005 µg/mL indicate that the method is sufficiently sensitive to identify low concentrations of Vitamin D-3 in samples. The robustness of the approach, which does not exhibit any substantial variations in reaction when the flow rate and mobile phase composition are changed, exemplifies the method's capabilities of adaptability and dependability in a variety of circumstances. Furthermore, on the basis of these validation results, it would appear that this HPLC approach is suited for routine measurement of vitamin D-3 in pharmaceutical formulations as well as bulk quantities. It would be interesting to gather information about whether or not the approach has been tested on a variety of formulations or matrices, as well as whether or not any difficulties were encountered throughout the testing process. [ABSTRACT FROM AUTHOR]